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Spasmolytic agenta b s t r a c t
Objective: Endoscopic retrograde cholangiopancreatography (ERCP) is a relatively complex procedure as
compared with other endoscopy which needs longer duration, duodenal relaxation and good sedation.
The aim of this study was to evaluate the efficacy and safety of magnesium sulphate as spasmolytic agent
during ERCP under general anaesthesia.
Design: A prospective randomized study.
Setting: Delivery room, operating room and postoperative recovery area.
Patients and method: Patients, who were treated for calcular obstructive jaundice by ERCP were random-
ized into two groups. The patients were randomized into two groups: G I, patients received 500 mg
magnesium sulphate in 100 ml saline 15 min before induction and G II, patients received
0.5 mg L-hyoscyamine sulphate before induction of anaesthesia.
Measurement: The primary outcome was duodenal relaxation during ERCP under general anaesthesia.
Secondary outcomes include changes of heart rate, changes in oxygen saturation, time needed for cannu-
lation, procedure difficulty, duration of the procedure, post-procedure complications, and the need of
post-procedure analgesia.
Results: Duodenal motility score was found to be 0.85 ± 1.47 in GI and 2.2 ± 3.08 in GII (P = 0.0001). The
number of patients who had no duodenal contraction was significantly more in GI. The success rate of
biliary cannulation is significantly higher in GI than in GII (58 (100%) vs 54 (93.1%), P = 0.04). The duration
of cannulation was significantly shorter in GI. The number of patients who developed pancreatitis, nausea
and vomiting was significantly less in GI. The pulse rate was found to be statistically less in GI at different
time follow-ups.
Conclusion: Magnesium sulphate is a safe spasmolytic agent during general anaesthesia that improves
the success rate of ERCP and it allows easy completion of the procedure by decreasing the duodenal
motility. It decreases the duration of the procedure, subsequently shortens the period of anaesthesia
and improves post procedure recovery. It reduces post ERCP pancreatitis, nausea and vomiting.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is a
useful tool for diagnosis and treatment of obstructive jaundice
[1–4]. ERCP needs patient cooperation and adequate sedation.
Although, some centres are undergoing ERCP with moderate seda-
tion, other centres performed ERCP under deep sedation or general
anaesthesia [2,5–8]. The Post ERCP morbidity and mortality ratewere 5–15% and 0.7–1.2%, respectively [2–6]. Lack of cooperation
has been found to be one of the leading cause for post ERCP mor-
bidity such as duodenal perforation, bleeding papillotomy, pancre-
atitis and cholecystitis [2,4,7,8].
Patients undergoing ERCP are at a risk of hypoxia and cardiac
problems due to prolonged duration of the procedure, semiprone
position, sedation, abdominal distension due to insufflations, med-
ication used to decrease duodenal motility, and associated car-
diopulmonary disorder [7,8]. So general anaesthesia during ERCP
is better than sedation alone to decrease the risk of hypoxia and
cardiac problem [5,6].otility
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and subsequent manipulation difficult. Pharmacologic drugs that
decrease or suppress duodenal motility are often needed during
ERCP [9,10]. L-hyoscyamine sulphate is antimuscarinic, anticholin-
ergic agent with antispasmodic effect. L-hyoscyamine sulphate is
commonly used to suppress duodenal motility during ERCP with
duration of action of 4 h but with some adverse effect. Other cen-
tres used intravenous glucagon but it has a short duration of action,
expensive and has many side effects including hyperglycaemia,
nausea, and vomiting [9].
Magnesium sulphate is a potent calcium antagonist that
makes relaxation of gastrointestinal tract and may decrease con-
traction. It has a potent bronchodilatation and so improves oxy-
genation during ERCP. Also, it has an analgesic effect and
decreases the incidence of post ERCP pancreatitis [11].
The aim of this study was to evaluate the efficacy and safety of
magnesium sulphate on duodenal motility and its impact on heart
rate and oxygen saturation during ERCP under general anaesthesia.2. Patients and Method
2.1. Patients
Patients, who were treated for calcular obstructive jaundice by
ERCP at Gastroenterology Surgical Center, Mansoura University,
Egypt, during the period from November 2014 to June 2015, will
be eligible for the study. Exclusion criteria included patients less
than 18 years or above 60 years, patients with severe cardiovascu-
lar disease, Respiratory, metabolic and endocrine diseases, patients
with BMI above 30 kg/m2 patients with impaired renal or hepatic
function or patients with anatomical deformities that will hinder
the procedure.
Informed consent was obtained from all patients to be included
in the study, after a careful explanation of the nature of the disease
and possible treatment with its complications. The study was
approved by the Institutional Review Board (IRB).
2.2. Pre ERCP assessment
All patients subjected to careful history taking, clinical exami-
nation (age, sex, medical diseases, symptoms and signs), laboratory
investigation (complete blood count, liver functions, creatinine,
serum amylase, and coagulation profile), radiological investiga-
tions (abdominal ultrasound, magnetic resonance cholangiopan-
creatography MRCP, and abdominal computerized tomography)
and Cardiopulmonary assessment by ECG, chest X ray and ECHO
in selected cases.
On arrival to the operating theatre, canula [18–20 G] was
inserted for all patients and infusion of lactated ringer solution at
a rate of 2–4 ml/kg/h for fluid deficits and maintenance supply.
2.3. Randomization
Patients enrolled in the study were randomized into two groups
using the closed envelope method. The envelopes were drawn and
opened by a nurse not otherwise engaged in the study in the
operating room. The patients were randomized into two groups:
Group I, patients received 500 mg magnesium sulphate in 100 ml
saline 15 min before induction and Group II, patients received
0.5 mg L-hyoscyamine sulphate before induction of anaesthesia.
2.4. Procedure
Anaesthetic plan was the same for both groups. All patients
were induced by propofol at a dose of 1.5–2 mg/kg I.V. bolusPlease cite this article in press as: El Hefnawy E, El Nakeeb A. Comparative stud
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syringe pump in a descending schedule rate [15–20 mic g/kg/
min]. Tracheal intubation was facilitated by administration of atra-
curium 0.5 mg/kg and controlled mechanical ventilation to keep
Etco2 around 35 mmHg; patients will be handled in prone posi-
tion; and at the end of the procedure anaesthesia will be
discontinued and the residual of neuromuscular blockade was
reversed with neostigmine 0.04 mg/kg plus atropine 0.02 mg/kg.
2.5. Data collected and definitions
Routine intraoperative monitoring for heart rate using lead II
ECG, non invasive mean blood pressure, pulse oximetry and
capnography will be recorded every 5 min. Anaesthesia time [time
from induction till discontinuation of propofol infusion] was
recorded.
Duodenal motility will be recorded according to this scale as
follows: [1] no contraction, [2] less than 5 cont./min, [3]
5–10 cont./min, [4] 11–15 cont./min and [5] continuous contrac-
tion [9,12]. Cannulation time is time needed from endoscope intro-
duction till cannulation of the papilla of Vater Procedure
difficulties will be assessed on a scale 1–4 with the following:
grade [1] a successful procedure that lasted less than 30 min, grade
[2] 30–60 min, grade [3] more than 60 min and grade [4] unsuc-
cessful procedure [9–11].
Postoperative analgesia according to verbal rating score will be
assessed. Postoperative sedation score will be assessed. Postopera-
tive concomitant complications will be recorded as nausea, vomit-
ing, bleeding, pancreatitis and cholangitis.
2.6. Assessments
The primary outcome was duodenal relaxation during ERCP
under general anaesthesia. Secondary outcomes include changes
of heart rate, changes in oxygen saturation, time needed for cannu-
lation, procedure difficulty, duration of the procedure, post-
procedure complications, and the need of post-procedure
analgesia.
Descriptive data were expressed as means and standard devia-
tions or as median with ranges for continuous data. Categorical
variables were described using frequency distributions. A P
value < .05 was considered statistically significant. Comparison of
variables was done by independent Student’s t-test for continuous
variables and Chi-square test for categorical variables. Statistical
analysis was done with the help of SPSS v. 17.3. Result
3.1. Patients data
The study flow chart is shown in Fig. 1. Of 336 consecutive
patients seen during the study period who had CBD stones, only
116 patients who had CBDS were included in the study. These
patients were randomly divided into two groups: Group I, patients
received 500 mg magnesium sulphate in 100 ml saline 15 min
before induction and Group II, patients received 0.5 mg
L-hyoscyamine sulphate before induction of anaesthesia. 220
patients were excluded from the study as present in Fig. 1.
3.2. Pre ERCP data
Demographic data were comparable in both groups as regards
age, sex, serum bilirubin, CBD diameter, and presence of DM. The
pre ERCP data of the both randomized groups are presented in
Table 1.y between magnesium sulphate and L-hyoscyamine on duodenal motility
t J Anaesth (2016), http://dx.doi.org/10.1016/j.egja.2016.10.001
Assessed for eligibility  (n= 336 )
***Enrollment
220 patients were excluded 
158 patients > 60 years
6 patients < 18 years
5  patients failed ERCP due to duodenal obstruction
29  patients had advanced liver cirrhosis
13 patients had BMI > 30





Allocated to  ERC L-hyoscyamine sulphate P (n= 58 )
Received allocated intervenon (n= 58 )
Allocated to ERCP with magnesium sulphate (n= 58  )
Received allocated intervenon (n= 58)
Lost to follow-up (n=0    ) Lost to follow-up (n=0 )
Analyzed (n= 58) Analyzed (n= 58  )
Figure 1. Flow diagram of the progress through the phases of a randomized trial (i.e., enrolment, intervention allocation, follow-up, and data analysis).
Table 1
Demographic data.
Magnesium sulphate group L-hyoscyamine sulphate group P value
Median age 43 (22–59) 45 (22–59) 0.33
Sex
Male 11 (19%) 13 (22.2%) 0.65
Female 47 (81%) 45 (77.6%)
BMI 23.9 (19–30) 24.3 (18–30) 0.56
Diabetes (DM) 4 (6.9%) 3 (5.2%) 0.69
Median serum bilirubin (mg/dl) 3.05 (0.6–10.3) 3.25 (0.5–12.8) 0.66
Serum amylase (U/L) 78 (45–155) 77 (40–150) 0.35
Median CBD diameter (mm) 13 (9–25) 13 (8–24) 0.24
Number of CBD stone
Single 46 (79.3%) 47 (81%) 0.82
Two 12 (20.7%) 11 (19%)
CBD stone size 10 (2–15) 10 (2–15) 0.6
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Duodenal motility score was found to be 0.85 ± 1.47 in magne-
sium sulphate group and 2.2 ± 3.08 in L-hyoscyamine group which
was statistically significant. Also, the number of patients who had
no duodenal contraction was significantly more in magnesium
sulphate Table 2.
The success rate of biliary cannulation is significantly higher in
magnesium sulphate group than in L-hyoscyamine group
(58 (100%) vs 54 (93.1%), P = 0.04) Table 2.
The duration of cannulation was significantly shorter in magne-
sium sulphate and also the total duration of anaesthesia is less in
magnesium sulphate group Table 2.
3.4. Post ERCP outcomes
Post ERCP recovery status significantly differed in both groups
at different time points after ERCP as shown in Table 3.Please cite this article in press as: El Hefnawy E, El Nakeeb A. Comparative stud
during ERCP under general anaesthesia: A prospective randomized study. EgypThe number of patients who developed pancreatitis was signif-
icantly more in L-hyoscyamine and all patients managed conserva-
tively and discharged after resolution of pancreatitis.
The number of patients who developed nausea and vomiting
was significantly more in L-hyoscyamine and they responded to
antiemetic drug and antiulcer.3.5. Changes in pulse rate, blood pressure and oxygen saturation
The most frequent adverse effect of L-hyoscyamine is tachycar-
dia. The pulse rate was found to be statistically lower in magne-
sium sulphate at different time follow-ups (at the beginning of
ERCP, after 5 min, and after 10 min) Table 4.
No significant difference was seen between both groups as
regards oxygen saturation, and mean blood pressure at different
time of procedures Table 4.y between magnesium sulphate and L-hyoscyamine on duodenal motility
t J Anaesth (2016), http://dx.doi.org/10.1016/j.egja.2016.10.001
Table 2
ERCP in both groups.
Magnesium sulphate group L-hyoscyamine sulphate group P value
Success rate of cannulation 58 (100%) 54 (93.1%) 0.04
Mean duodenal motility/min 0.85 ± 1.47 (0–8) 2.2 ± 3.08 (0–12) 0.0001
Duodenal motility
No contraction 47 (81%) 34 (58.5%) 0.03
Less than 5 cont./min 7 (12.1%) 16 (27.6%)
5–10 cont./min 4 (6.9%) 7 (12.1%)
Continuous contraction 0 1 (1.7%)
Median duration needed till cannulation (min) 3.5 (0.5–12) 6 (1–15) 0.0001
Number of pancreatic cannulation 0.12 ± 0.46 (0–2) 0.29 ± 0.87 (0–4) 0.18
Anaesthetic period (min) 30 (16–55) 38 (20–89) 0.08
Endoscopist satisfaction
Satisfied 52 (89.7%) 46 (79.3%) 0.12
Not satisfied 6 (10.3%) 12 (20.7%)
Outcome of ERCP
Failed cannulation 0 4 (6.9%) 0.21
CBD clearance 53 (91.4%) 50 (86.2%)
Failed clearance of CBDS and stent application 5 (8.6%) 4 (6.9%)
Table 3







Post ERCP status at the end of procedure
1. Awake, anxious 0 3 (5.2%) 0.002
2. Awake, cooperative 0 2 (3.4%)
3. Awake, respond to
command only
0 5 (8.6%)
4. Asleep, brisk response 4 (6.9%) 7 (12.1%)
5. Asleep, sluggish
response
14 (24.1%) 21 (36.2%)
6. Asleep, no response 40 (69%) 20 (34.5%)
Post ERCP status after 10 min
1. Awake, anxious 0 4 (6.9%) 0.0001
2. Awake, cooperative 6 (10.3%) 2 (3.4%)
3. Awake, respond to
command only
4 (6.9%) 18 (31%)
4. Asleep, brisk response 9 (15.5%) 24 (41.4%)
5. Asleep, sluggish
response
30 (51.7%) 10 (17.2%)
6. Asleep, no response 9 (15.5%) 0
Post ERCP status after 30 min
1. Awake, anxious 19 (32.8%) 33 (56.9%) 0.01
2. Awake, cooperative 18 (31%) 18 (31%)
3. Awake, respond to
command only
15 (25.9%) 4 (6.9%)




6. Asleep, no response 0 0
Post ERCP status after 60 min
1. Awake, anxious 0 0 0.0001
2. Awake, cooperative 42 (72.1%) 55 (94.8%)
3. Awake, respond to
command only
14 (24.1%) 0




6. Asleep, no response 0 0
Number of patients need
analgesic
7 (12.1%) 9 (15.5%) 0.12
Nausea and vomiting 5 (8.6%) 15 (25.9%) 0.01
Serum amylase 79.5 (49–1200) 80 (60–1200) 0.3
Number of patients
developed Pancreatitis
2 (3.4%) 8 (13.8%) 0.05
Median serum bilirubin
(mg/dl)
2 (0.6–9.4) 2 (0.6–9.5) 0.55
Table 4








Pre ERCP pulse rate 75 (60–94) 74 (60–94) 0.9
Pulse rate at the beginning
of ERCP
84 (64–99) 92 (80–102) 0.0001
Pulse rate after 5 min 83 (69–110) 96 (78–120) 0.0001
Pulse rate after 10 min 81 (62–105) 92 (82–120) 0.0001
Mean blood pressure (mmHg)
Pre ERCP mean blood
pressure
90 (67–108) 87 (69–104) 0.15
Mean blood pressure at the
beginning of ERCP
89 (68–101) 90(68–104) 0.93
Mean blood pressure after
5 min
86 (65–104) 87 (65–102) 0.57
Mean blood pressure after
10 min
88 (70–106) 88 (69–105) 0.97
Oxygen saturation
Pre ERCP oxygen saturation 99 (98–100) 99 (98–100) 0.9
Oxygen saturation at the
beginning of ERCP
100 (98–100) 99 (98–100) 0.87
Oxygen saturation after
5 min
100 (98–100) 100 (99–100) 0.85
Oxygen saturation after
10 min
100 (98–100) 100 (99–100) 0.65
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Endoscopic retrograde cholangiopancreatography (ERCP) is
commonly used in diagnosis and management of biliary and pan-
creatic diseases. ERCP is a relatively complex procedure as com-
pared with other endoscopy and needs a longer duration. During
ERCP duodenal motility has a great impact on the outcome as it
makes hard to cannulate the papilla and other manipulations
[11]. Spasmolytic drugs are widely used during ERCP for reduction
or inhibition of duodenal motility and to make the papillary cannu-
lation easy. For this aim, drugs such as glucagon and L-
hyoscyamine sulphate are widely used [9,10,12–15].
ERCP needs patient cooperation, which requires adequate seda-
tion and pain relief. Patients undergoing ERCP have been found to
be more irritable than those undergoing a routine gastrointestinaly between magnesium sulphate and L-hyoscyamine on duodenal motility
t J Anaesth (2016), http://dx.doi.org/10.1016/j.egja.2016.10.001
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be one of the causes for post-ERCP morbidity such as pancreatitis
and visceral perforation [16,17]. ERCP is a prolonged manoeuvre,
and hence adequate sedation and patient co-operation are the
cornerstones for its successful completion. Although majority of
ERCPs are performed under moderate sedation, others do it under
deep sedation or general anaesthesia. Hypoxia is an inherent risk
associated with sedation. Patients undergoing ERCP are at a risk
of oxygen desaturation due to various causes including the prone
position, associated cardiopulmonary disorder, prolonged dura-
tion, sedation used, and other drugs used. Drugs-induced respira-
tory depression has been found to be the most common leading
cause of endoscopy-related mortality and morbidity. There has
been no evidence regarding the safest and the most effective
method of sedation [6]. In our centre, in recent years we routinely
perform ERCP under general anaesthesia and endotracheal
intubation and these allow safe ERCP and improve the results
markedly [3].
Spasmolytic drugs widely used during ERCP for reduction or
inhibition of duodenal motility may affect the patients who are
under anaesthesia [13–15]. The impact of spasmolytic agent on
pulse, blood pressure, oxygen saturation and duodenal motility
must be monitored by anaesthesiologist.
L-hyoscyamine is an antimuscarinic, anticholinergic agent with
antispasmodic properties so, it is widely used during ERCP to
reduce the duodenal motility and subsequently allow easy cannu-
lation and decrease the duration of procedure and time of anaes-
thesia. It has some anticholinergic adverse effects on the heart
leading to tachycardia, xerostomia, and urinary retention. There-
fore, it should be used with precaution in cases with bronchial
asthma, thyrotoxicosis, and heart disorders [13–15].
The spasmolytic effect of magnesium in humans has been found
in a few cases, including a patient receiving parenteral magnesium
sulphate for tocolysis, and in patients on magnesium laxatives for
chronic constipation; the effect was increased secondary to cal-
cium channel blocker use. Magnesium has a nonspecific calcium
channel blocker effect, so its action may be increased by calcium
channel blockers and hypocalcaemia, and can be partially reversed
with calcium injection [18–20]. In this study the use of magnesium
sulphate during ERCP induces more duodenal relaxation and
decreases duodenal contraction as well as has inhibitory effect
on sphincter of Oddi more than in L-hyoscyamine. So, it makes
papillary cannulation easier after magnesium sulphate administra-
tion. No adverse effect was reported for magnesium sulphate. It
decreases the incidence of post ERCP pancreatitis.
Lahoti et al. [11] performed a prospective randomized study
that included 308 patients who were randomized to receive intra-
venous glucagon or intravenous L-hyoscyamine during ERCP. L-
hyoscyamine was found to be slightly less effective on duodenal
motility and had more side effect at 2 h after ERCP. However, this
did not lead to procedure difficulty or success. L-hyoscyamine is
much less expensive than glucagon, and L-hyoscyamine has been
shown to have similar efficacy to glucagon. Hui and Ostroff [20]
in a randomized study, reported that L-hyoscyamine was associ-
ated with more xerostomia and tachycardia, but did not affect
the procedures and the success rates were the same.
Post-anaesthesia recovery has to be adequate before the patient
can be shifted to the ward. Smooth recovery was affected by many
factors including duration of procedure, distention of the abdomen,
complications after ERCP, haemodynamics, oxygen saturation,
Post-operative nausea, retching and vomiting and medication such
as spasmolytic agent. Propofol is known to have antiemetic effect.
Subhypnotic doses of propofol (0.5 mg/kg) have been found to pre-
vent nausea and retching for 6 h post-procedure [6,21]. In this
study, the recovery is more smooth in magnesium sulphate groupPlease cite this article in press as: El Hefnawy E, El Nakeeb A. Comparative stud
during ERCP under general anaesthesia: A prospective randomized study. Egypbecause the duration of anaesthesia is shorter than in L-
hyoscyamine group.
The present prospective randomized study is subject to one lim-
itation. The sample size was small and not calculated. Further
prospective randomized studies with larger sample sizes are
required to confirm these results.5. Conclusion
ERCP is a relatively complex procedure as compared with other
gastrointestinal endoscopies and requires a longer duration. Mag-
nesium sulphate is a safe spasmolytic agent during general anaes-
thesia that improves the success rate of ERCP and it allows easy
completion of the procedure by decreasing the duodenal motility.
It decreases the duration of the procedure, subsequently shortens
the period of anaesthesia and improves post procedure recovery.
It reduces post ERCP pancreatitis.Author contributions
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